RxDoctor Payments Data

James Gardner, MD

Family Medicine · New Wilmington, PANPI 1194766162

Payments from drug & device makers

$18,720in general payments, 2019–2025

Across 1,035 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Pfizer$2K
  • Amgen$2K
  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$1K
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$18,53199%
  • Education$1891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,720 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$67,451
Medicare patients
131
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$91,858
JardianceEmpagliflozin88$86,219
XareltoRivaroxaban153$77,369
FarxigaDapagliflozin Propanediol76$66,183
MounjaroTirzepatide44$49,067
Teriparatide17$48,456
OzempicSemaglutide25$43,801
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$32,886
GlyxambiEmpagliflozin/Linagliptin38$32,384
ProliaDenosumab14$23,831
JanuviaSitagliptin Phosphate20$23,218
Repatha SyringeEvolocumab18$13,031
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$10,357
Soliqua 100-33Insulin Glargine/Lixisenatide12$9,838
LinzessLinaclotide15$8,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$806$118,603126 claims
PfizerEliquis$1,746$91,858190 claims
Johnson & JohnsonXarelto$209$77,369153 claims
AstraZenecaFarxiga$2,669$66,18376 claims
Lilly USA, LLCMounjaro$837$49,06744 claims
Novo NordiskOzempic, Novolog$1,396$46,91138 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,494$37,50757 claims
AmgenProlia$1,742$23,83114 claims
MerckJanuvia$458$23,21820 claims
AbbVieLinzess, Synthroid$1,559$11,60154 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$100$9,83812 claims
Astellas Pharma US IncMyrbetriq$422$5,73437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Wilmington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →